Compass Therapeutics to present tovecimig data orally at ESMO Congress 2026

The acceptance gives the biotech company a higher-profile slot at one of oncology’s major scientific meetings, signaling investor focus on upcoming clinical readouts.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.